Cathepsin D as a potential prognostic marker for lung adenocarcinoma

Takahiro Mimae, Koji Tsuta, Akiko M. Maeshima, Morihito Okada, Hisao Asamura, Tadashi Kondo, Hitoshi Tsuda

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We previously identified cathepsin D as a possible marker for lung adenocarcinoma (AD). The purpose of the present study is to evaluate the correlation between cathepsin D expression and clinicopathological findings or prognosis. We conducted immunohistochemistry (IHC) to assess 150 AD tissues. For these 150 tumors, TTF-1 expression, . EGFR and . KRAS gene mutations, and . ALK rearrangements had already been examined. Cathepsin D expression was detected in 44% (66 of 150, IHC score ≥1+) and 27.3% (41 of 150, IHC score ≥2+). Cathepsin D-positive (IHC score ≥2+) tumors were more poorly differentiated than cathepsin D-negative ones, while all lepidic predominant invasive adenocarcinomas showed no cathepsin D expression. Univariate analysis revealed a poor prognosis for cathepsin D-positive lung AD patients with an IHC score ≥2+ (. P=. 0.044). Cathepsin D expression was more frequent in TTF-1-negative than in TTF-1-positive ADs (. P=. 0.034), and more frequent in ADs with . EGFR wild genotype than mutant . EGFR (. P<. 0.001). Regarding AD patients with . ALK rearrangements, 4 were positive for Cathepsin D, while 2 were negative. Cathepsin D expression is indicated to be a possible prognostic marker for lung AD and to correlate with a more poorly differentiated form.

Original languageEnglish
Pages (from-to)534-540
Number of pages7
JournalPathology Research and Practice
Volume208
Issue number9
DOIs
Publication statusPublished - 2012 Sep 15
Externally publishedYes

Fingerprint

Cathepsin D
Immunohistochemistry
Adenocarcinoma
Adenocarcinoma of lung
Neoplasms
Genotype

Keywords

  • Cathepsin D
  • Differentiation
  • Lung adenocarcinoma
  • Predictive factor
  • Tumor marker

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Mimae, T., Tsuta, K., Maeshima, A. M., Okada, M., Asamura, H., Kondo, T., & Tsuda, H. (2012). Cathepsin D as a potential prognostic marker for lung adenocarcinoma. Pathology Research and Practice, 208(9), 534-540. https://doi.org/10.1016/j.prp.2012.05.020

Cathepsin D as a potential prognostic marker for lung adenocarcinoma. / Mimae, Takahiro; Tsuta, Koji; Maeshima, Akiko M.; Okada, Morihito; Asamura, Hisao; Kondo, Tadashi; Tsuda, Hitoshi.

In: Pathology Research and Practice, Vol. 208, No. 9, 15.09.2012, p. 534-540.

Research output: Contribution to journalArticle

Mimae, T, Tsuta, K, Maeshima, AM, Okada, M, Asamura, H, Kondo, T & Tsuda, H 2012, 'Cathepsin D as a potential prognostic marker for lung adenocarcinoma', Pathology Research and Practice, vol. 208, no. 9, pp. 534-540. https://doi.org/10.1016/j.prp.2012.05.020
Mimae, Takahiro ; Tsuta, Koji ; Maeshima, Akiko M. ; Okada, Morihito ; Asamura, Hisao ; Kondo, Tadashi ; Tsuda, Hitoshi. / Cathepsin D as a potential prognostic marker for lung adenocarcinoma. In: Pathology Research and Practice. 2012 ; Vol. 208, No. 9. pp. 534-540.
@article{968d6c22fc3b4440aec82486fd04f954,
title = "Cathepsin D as a potential prognostic marker for lung adenocarcinoma",
abstract = "We previously identified cathepsin D as a possible marker for lung adenocarcinoma (AD). The purpose of the present study is to evaluate the correlation between cathepsin D expression and clinicopathological findings or prognosis. We conducted immunohistochemistry (IHC) to assess 150 AD tissues. For these 150 tumors, TTF-1 expression, . EGFR and . KRAS gene mutations, and . ALK rearrangements had already been examined. Cathepsin D expression was detected in 44{\%} (66 of 150, IHC score ≥1+) and 27.3{\%} (41 of 150, IHC score ≥2+). Cathepsin D-positive (IHC score ≥2+) tumors were more poorly differentiated than cathepsin D-negative ones, while all lepidic predominant invasive adenocarcinomas showed no cathepsin D expression. Univariate analysis revealed a poor prognosis for cathepsin D-positive lung AD patients with an IHC score ≥2+ (. P=. 0.044). Cathepsin D expression was more frequent in TTF-1-negative than in TTF-1-positive ADs (. P=. 0.034), and more frequent in ADs with . EGFR wild genotype than mutant . EGFR (. P<. 0.001). Regarding AD patients with . ALK rearrangements, 4 were positive for Cathepsin D, while 2 were negative. Cathepsin D expression is indicated to be a possible prognostic marker for lung AD and to correlate with a more poorly differentiated form.",
keywords = "Cathepsin D, Differentiation, Lung adenocarcinoma, Predictive factor, Tumor marker",
author = "Takahiro Mimae and Koji Tsuta and Maeshima, {Akiko M.} and Morihito Okada and Hisao Asamura and Tadashi Kondo and Hitoshi Tsuda",
year = "2012",
month = "9",
day = "15",
doi = "10.1016/j.prp.2012.05.020",
language = "English",
volume = "208",
pages = "534--540",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "9",

}

TY - JOUR

T1 - Cathepsin D as a potential prognostic marker for lung adenocarcinoma

AU - Mimae, Takahiro

AU - Tsuta, Koji

AU - Maeshima, Akiko M.

AU - Okada, Morihito

AU - Asamura, Hisao

AU - Kondo, Tadashi

AU - Tsuda, Hitoshi

PY - 2012/9/15

Y1 - 2012/9/15

N2 - We previously identified cathepsin D as a possible marker for lung adenocarcinoma (AD). The purpose of the present study is to evaluate the correlation between cathepsin D expression and clinicopathological findings or prognosis. We conducted immunohistochemistry (IHC) to assess 150 AD tissues. For these 150 tumors, TTF-1 expression, . EGFR and . KRAS gene mutations, and . ALK rearrangements had already been examined. Cathepsin D expression was detected in 44% (66 of 150, IHC score ≥1+) and 27.3% (41 of 150, IHC score ≥2+). Cathepsin D-positive (IHC score ≥2+) tumors were more poorly differentiated than cathepsin D-negative ones, while all lepidic predominant invasive adenocarcinomas showed no cathepsin D expression. Univariate analysis revealed a poor prognosis for cathepsin D-positive lung AD patients with an IHC score ≥2+ (. P=. 0.044). Cathepsin D expression was more frequent in TTF-1-negative than in TTF-1-positive ADs (. P=. 0.034), and more frequent in ADs with . EGFR wild genotype than mutant . EGFR (. P<. 0.001). Regarding AD patients with . ALK rearrangements, 4 were positive for Cathepsin D, while 2 were negative. Cathepsin D expression is indicated to be a possible prognostic marker for lung AD and to correlate with a more poorly differentiated form.

AB - We previously identified cathepsin D as a possible marker for lung adenocarcinoma (AD). The purpose of the present study is to evaluate the correlation between cathepsin D expression and clinicopathological findings or prognosis. We conducted immunohistochemistry (IHC) to assess 150 AD tissues. For these 150 tumors, TTF-1 expression, . EGFR and . KRAS gene mutations, and . ALK rearrangements had already been examined. Cathepsin D expression was detected in 44% (66 of 150, IHC score ≥1+) and 27.3% (41 of 150, IHC score ≥2+). Cathepsin D-positive (IHC score ≥2+) tumors were more poorly differentiated than cathepsin D-negative ones, while all lepidic predominant invasive adenocarcinomas showed no cathepsin D expression. Univariate analysis revealed a poor prognosis for cathepsin D-positive lung AD patients with an IHC score ≥2+ (. P=. 0.044). Cathepsin D expression was more frequent in TTF-1-negative than in TTF-1-positive ADs (. P=. 0.034), and more frequent in ADs with . EGFR wild genotype than mutant . EGFR (. P<. 0.001). Regarding AD patients with . ALK rearrangements, 4 were positive for Cathepsin D, while 2 were negative. Cathepsin D expression is indicated to be a possible prognostic marker for lung AD and to correlate with a more poorly differentiated form.

KW - Cathepsin D

KW - Differentiation

KW - Lung adenocarcinoma

KW - Predictive factor

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=84865280129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865280129&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2012.05.020

DO - 10.1016/j.prp.2012.05.020

M3 - Article

VL - 208

SP - 534

EP - 540

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 9

ER -